Literature DB >> 26751161

Discovery of Isonicotinamides as Highly Selective, Brain Penetrable, and Orally Active Glycogen Synthase Kinase-3 Inhibitors.

Guanglin Luo1, Ling Chen1, Catherine R Burton1, Hong Xiao1, Prasanna Sivaprakasam1, Carol M Krause1, Yang Cao1, Nengyin Liu1, Jonathan Lippy1, Wendy J Clarke1, Kimberly Snow1, Joseph Raybon1, Vinod Arora1, Matt Pokross1, Kevin Kish1, Hal A Lewis1, David R Langley1, John E Macor1, Gene M Dubowchik1.   

Abstract

GSK-3 is a serine/threonine kinase that has numerous substrates. Many of these proteins are involved in the regulation of diverse cellular functions, including metabolism, differentiation, proliferation, and apoptosis. Inhibition of GSK-3 may be useful in treating a number of diseases including Alzheimer's disease (AD), type II diabetes, mood disorders, and some cancers, but the approach poses significant challenges. Here, we present a class of isonicotinamides that are potent, highly kinase-selective GSK-3 inhibitors, the members of which demonstrated oral activity in a triple-transgenic mouse model of AD. The remarkably high kinase selectivity and straightforward synthesis of these compounds bode well for their further exploration as tool compounds and therapeutics.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 26751161     DOI: 10.1021/acs.jmedchem.5b01550

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  7 in total

1.  Discovery of a Highly Selective Glycogen Synthase Kinase-3 Inhibitor (PF-04802367) That Modulates Tau Phosphorylation in the Brain: Translation for PET Neuroimaging.

Authors:  Steven H Liang; Jinshan Michael Chen; Marc D Normandin; Jeanne S Chang; George C Chang; Christine K Taylor; Patrick Trapa; Mark S Plummer; Kimberly S Para; Edward L Conn; Lori Lopresti-Morrow; Lorraine F Lanyon; James M Cook; Karl E G Richter; Charlie E Nolan; Joel B Schachter; Fouad Janat; Ye Che; Veerabahu Shanmugasundaram; Bruce A Lefker; Bradley E Enerson; Elijahu Livni; Lu Wang; Nicolas J Guehl; Debasis Patnaik; Florence F Wagner; Roy Perlis; Edward B Holson; Stephen J Haggarty; Georges El Fakhri; Ravi G Kurumbail; Neil Vasdev
Journal:  Angew Chem Int Ed Engl       Date:  2016-06-29       Impact factor: 15.336

2.  Structural Basis for Achieving GSK-3β Inhibition with High Potency, Selectivity, and Brain Exposure for Positron Emission Tomography Imaging and Drug Discovery.

Authors:  Vadim Bernard-Gauthier; Andrew V Mossine; Ashley Knight; Debasis Patnaik; Wen-Ning Zhao; Chialin Cheng; Hema S Krishnan; Lucius L Xuan; Peter S Chindavong; Surya A Reis; Jinshan Michael Chen; Xia Shao; Jenelle Stauff; Janna Arteaga; Phillip Sherman; Nicolas Salem; David Bonsall; Brenda Amaral; Cassis Varlow; Lisa Wells; Laurent Martarello; Shil Patel; Steven H Liang; Ravi G Kurumbail; Stephen J Haggarty; Peter J H Scott; Neil Vasdev
Journal:  J Med Chem       Date:  2019-10-21       Impact factor: 7.446

3.  Radiosynthesis and evaluation of [11C]CMP, a high affinity GSK3 ligand.

Authors:  Jaya Prabhakaran; Kiran Kumar Solingapuram Sai; Anirudh Sattiraju; Akiva Mintz; J John Mann; J S Dileep Kumar
Journal:  Bioorg Med Chem Lett       Date:  2019-01-25       Impact factor: 2.823

Review 4.  Glycogen Synthase Kinase-3 Inhibitors: Preclinical and Clinical Focus on CNS-A Decade Onward.

Authors:  Sara Melisa Arciniegas Ruiz; Hagit Eldar-Finkelman
Journal:  Front Mol Neurosci       Date:  2022-01-21       Impact factor: 5.639

5.  A Unique GSK-3β inhibitor B10 Has a Direct Effect on Aβ, Targets Tau and Metal Dyshomeostasis, and Promotes Neuronal Neurite Outgrowth.

Authors:  Xiao-Long Shi; Ning Yan; Ying-Jie Cui; Zhao-Peng Liu
Journal:  Cells       Date:  2020-03-07       Impact factor: 6.600

6.  The selective GSK3 inhibitor, SAR502250, displays neuroprotective activity and attenuates behavioral impairments in models of neuropsychiatric symptoms of Alzheimer's disease in rodents.

Authors:  Guy Griebel; Jeanne Stemmelin; Mati Lopez-Grancha; Denis Boulay; Gerald Boquet; Franck Slowinski; Philippe Pichat; Sandra Beeské; Shinji Tanaka; Akiko Mori; Masatake Fujimura; Junichi Eguchi
Journal:  Sci Rep       Date:  2019-12-02       Impact factor: 4.379

Review 7.  When Good Kinases Go Rogue: GSK3, p38 MAPK and CDKs as Therapeutic Targets for Alzheimer's and Huntington's Disease.

Authors:  Santosh R D'Mello
Journal:  Int J Mol Sci       Date:  2021-05-31       Impact factor: 5.923

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.